ProShares Ultra NASDAQ Biotechnology
BIB
24 hedge funds and large institutions have $6.47M invested in ProShares Ultra NASDAQ Biotechnology in 2024 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 3 increasing their positions, 5 reducing their positions, and 4 closing their positions.
75% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 4
43% more capital invested
Capital invested by funds: $4.52M → $6.47M (+$1.95M)
14% more funds holding
Funds holding: 21 → 24 (+3)
2.86% more ownership
Funds ownership: 4.67% → 7.53% (+2.9%)
21% less call options, than puts
Call options by funds: $764K | Put options by funds: $972K
40% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$891K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$682K |
| 3 |
IMC Chicago
Chicago,
Illinois
|
+$656K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$496K |
| 5 |
Jane Street
New York
|
+$245K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TFA
Toth Financial Advisory
Leesburg,
Virginia
|
-$744K |
| 2 |
TCBWMS
Texas Capital Bank Wealth Management Services
Dallas,
Texas
|
-$288K |
| 3 |
JP Morgan Chase
New York
|
-$144K |
| 4 |
CIC
Chase Investment Counsel
Charlottesville,
Virginia
|
-$84.1K |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$22.9K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
JP Morgan Chase
New York
| – | -$144K | -2,500 | Closed |
|
|
TC
27
Truvestments Capital
Sarasota,
Florida
| – | -$7.19K | -125 | Closed |
|
28
Bank of America
Charlotte,
North Carolina
| – | -$575 | -10 | Closed |
|
BIB Hedge Fund Activity: Q2 2024 in Review
24 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in ProShares Ultra NASDAQ Biotechnology (BIB) for Q2 2024, worth a combined $6.47M — up 43% from $4.52M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new BIB positions and 4 closed out — a net gain of 3 holders — while 3 added to existing stakes and 5 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $891K. The largest seller was Toth Financial Advisory, cutting an estimated $744K.
- 24 institutional investors held ProShares Ultra NASDAQ Biotechnology (BIB) as of Q2 2024, up from 21 in Q1 2024.
- Funds reported $6.47M of ProShares Ultra NASDAQ Biotechnology stock for Q2 2024, up 43% quarter-over-quarter.
- 7 funds opened new ProShares Ultra NASDAQ Biotechnology positions in Q2 2024 and 4 closed out, a net change of +3 holders.
- The largest ProShares Ultra NASDAQ Biotechnology buyer in Q2 2024 was Susquehanna International Group, an estimated $891K added.
- The largest ProShares Ultra NASDAQ Biotechnology seller in Q2 2024 was Toth Financial Advisory, an estimated $744K sold.
Based on aggregated 13F filings for Q2 2024.